GE Healthcare Acquires Zionexa
2021年5月6日 - 10:51PM
Dow Jones News
By Michael Dabaie
General Electric Co.'s healthcare business said it acquired
Zionexa, a company focused on in-vivo oncology and neurology
biomarkers.
GE Healthcare said it aims to develop and bring to market
Zionexa's pipeline biomarkers, as well as the recently Food and
Drug Administration-approved positron emission tomography imaging
agent, Cerianna. Cerianna is used as an adjunct to biopsy for the
detection of estrogen receptor positive lesions to help inform
treatment selection for patients with recurrent or metastatic
breast cancer.
Zionexa was formed in 2018 and headquartered in Aubiere, France.
The company employs 24 people in France and the U.S., all of whom
will transfer to GE Healthcare. GE Healthcare said it will hire
about 70 new dedicated employees within the company's U.S.
Pharmaceutical Diagnostics team.
Financial terms of the acquisition aren't being disclosed, the
company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 06, 2021 09:36 ET (13:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
General Electric (NYSE:GE)
過去 株価チャート
から 2 2024 まで 3 2024
General Electric (NYSE:GE)
過去 株価チャート
から 3 2023 まで 3 2024